Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease.
Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 8, 2022 | Series A | $15.10M | 6 | Broadview Ventures Hatteras Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Broadview Ventures | Yes | Series A |
Hatteras Venture Partners | Yes | Series A |
Laerdal Million Lives Fund | — | Series A |
OSF Ventures | — | Series A |
Portal Innovations | — | Series A |
UnityPoint Health Ventures | — | Series A |